| abstract |
Compounds within the scope of the present invention have Formula 1 or a salt or prodrug thereof, wherein ring A is selected from alicyclic; ring B is aryl; R 1 is (C 1 -C 10) alkyl, ( C3-C10) selected from cycloalkyl, halo, aryl and heteroaryl; and R2 and R3 are independently selected from hydrogen and (C1-C6) alkyl. Compounds of the present disclosure may have an IRAK4 / TAK1 selectivity of 0.003 μM to 3.7 μM IRAK4 IC50; 0.008 μM to 132 μM TAK1 IC50; and / or 1 to 450. Certain compounds may have 100-500 IRAK4 / TAK1 selectivity. The compositions of the present disclosure may be formulated as pharmaceutical compositions. Also disclosed are uses of the compounds and / or compositions. The method may comprise the step of administering to the subject an effective amount of a compound within the scope of the present invention that selectively inhibits IRAK 1 and / or IRAK 4 specifically over TAK1. |